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Abstract 
 
The SCreening for Osteoporosis in Older women for the Prevention of fracture [SCOOP] study was a 
community-based screening intervention, in women aged 70 to 85 years in the UK.  In the screening 
arm, licensed osteoporosis treatments were recommended in women identified to be at high risk of 
hip fracture using the FRAX risk assessment tool (including BMD measurement).  In the control arm, 
standard care was provided.  Screening led to a 28% reduction in hip fractures over 5 years.  In this 
planned post hoc analysis, we wished to examine for interactions between screening effectiveness 
on fracture outcome (any, osteoporotic and hip fractures) on the one hand and baseline FRAX 10-
year probability of hip fracture on the other.  All analyses were conducted on an intention-to-treat 
basis, based on the group to which women were randomised, irrespective of whether screening was 
completed.   
Of 12,483 eligible participants, 6,233 women were randomised to screening, with treatment 
recommended in 898 (14.4%).  No evidence of an effect or interaction was observed for the 
outcomes of any fracture or osteoporotic fracture.  In the screening arm, 54 fewer hip fractures 
were observed than in the control arm (164 versus 218, 2.6% vs 3.5%), and commensurate with 
treatment being targeted to those at highest hip fracture risk, the effect on hip fracture increased 
with baseline FRAX hip fracture probability (p=0.021 for interaction); for example, at the 10th 
percentile of baseline FRAX hip probability (2.6%), there was no evidence that hip fractures were 
reduced (HR 0.93, 0.71 to 1.23) but at the 90th percentile (16.6%), there was a 33% reduction (HR 
0.67, 0.53 to 0.84).  Prior fracture and parental history of hip fracture positively influenced screening 
effectiveness on hip fracture risk. 
We conclude that women at high risk of hip fracture based on FRAX probability are responsive to 
appropriate osteoporosis management. 
 
 
Funding 
The Arthritis Research United Kingdom (ARUK), formerly the Arthritis Research Campaign (ARC), 
and the Medical Research Council (MRC) of the UK jointly funded this trial. 
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Introduction 
 
Over the last few years, treatment based on the absolute risk of fracture has been incorporated 
into many national and international guidelines, given the availability of validated fracture risk 
assessment tools such as FRAX®, launched in 2008.(1,2)  For example, in the UK, specific age-
dependent intervention thresholds based on 10-year probability of fracture are advocated by the 
National Osteoporosis Guideline Group in their recent NICE-accredited guidance.(3)   A cornerstone 
of the clinical utility of fracture risk tools is that the risk identified should be reversible by bone 
targeted therapies, and a number of post hoc analyses of phase III clinical trials have demonstrated 
that this is the case for risk identified by FRAX.(4-11)  Very recently, the first study that prospectively 
screened patients using FRAX probabilities to assess fracture risk (the SCOOP ‘SCreening for 
Osteoporosis in Older women for the Prevention of fracture’ study) has been published.(12)  This UK 
multi-centre study, largely primary care-based, assessed the effectiveness of a FRAX-based, 
community screening programme in women aged 70 to 85 years, with treatment targeted at 
women at high risk of hip fracture, compared to a control group receiving standard clinical care.  
The approach appears to be acceptable to both patients and GPs.(13)  During five years of follow up, 
prescriptions for anti-osteoporosis medications were more frequent, and hip fracture incidence 
lower, in the screening intervention arm compared with the control arm (Table 1). Anti-
osteoporosis medications were particularly frequently prescribed in those intervention participants 
classified as at high fracture risk, and so we hypothesized that the effect of screening to reduce hip 
fractures would be greatest in women with higher baseline FRAX probability, with a consequent 
interaction between baseline FRAX hip fracture probability and screening effectiveness. 
 
Methods 
The SCOOP clinical study was a pragmatic, unblinded, two group, parallel, randomised 
controlled trial to assess the effectiveness and cost-effectiveness of screening to prevent 
fractures in older women; the design and results have been published previously.(12,14)  In brief, 
women age 70-85 years, not already on osteoporosis medications but suitable to participate, 
were approached through primary care lists in and around seven regions of England.  Written, 
informed consent was obtained from all agreeing to participate, and they completed a self-
filled questionnaire capturing the FRAX risk factors prior to being randomised to the 
intervention (screening) or control arm.  Baseline data comprised age, sex, height and weight 
for Body Mass Index (BMI) calculation, and dichotomised risk variables including a prior fragility 
fracture since the age of 50 years, parental history of hip fracture, current tobacco smoking, any 
long-term use of oral glucocorticoids, rheumatoid arthritis, other causes of secondary 
osteoporosis and daily alcohol consumption of ≥3 units daily. If the respondent did not know 
the answer to an individual question a negative response was assumed. 
In the screening arm, the baseline risk factor questionnaire was used to calculate the 10-year 
probability of hip fracture using the FRAX risk algorithm.  Women deemed at moderate to high risk 
of hip fracture were invited to undergo a dual-energy x-ray absorptiometry (DXA) measurement of 
femoral neck BMD measurement and the 10-year hip fracture probability was recalculated with 
inclusion of BMD. The final risk category (low or high) was communicated to the participant and 
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family doctor by letter; participants remaining at high risk after incorporation of BMD into FRAX 
were advised to make an appointment with their family doctor to discuss treatment options. 
In the control arm, apart from a letter to the GP informing them of their patient participating in the 
study, no additional information was provided and they received usual care. The baseline 10-year 
FRAX probabilities, without the inclusion of BMD, were calculated at the end of the trial for 
comparative purposes only. 
During five years of follow up, exposure to osteoporosis treatment was higher in the screening arm 
with around 24% of the screening arm participants receiving at least one prescription for anti-
osteoporosis medication compared with 16% of the control arm.  The difference reflected a high 
uptake of treatment in the high risk group within the screening arm with 703 women (78·3% of the 
high risk group) having received at least one prescription of anti-osteoporosis medication within six 
months of randomisation. 
 
Fracture Outcomes 
Only verified fractures, at any anatomical site, within the five-year follow-up period, were included 
as outcomes.  In brief, we captured self-reported fractures as well as searching routine Hospital 
Episode Statistics data, comprising information on hospital inpatient stays and emergency 
department attendance, together with primary care records to identify fractures in any of the study 
participants from the point of randomisation until the end of follow-up. Only independently 
confirmed fractures were included.  Incident osteoporosis-related fractures were defined as those 
excluding the hands, feet, nose, skull or cervical vertebrae. Hip fractures were defined as verified 
fractures with a specific description of ‘neck of femur’ or ‘proximal femur’. 
 
Statistical Analysis 
As BMD measurements were not undertaken in all participants, the FRAX 10-year hip fracture 
probability calculated without BMD was used in the analyses as this was available in both the control 
and intervention groups.  A Poisson model was used to study the relationship between age, the time 
since baseline, invitation for screening, and FRAX 10-year probability of hip fracture on the one hand 
and on the other hand, the risk of any fracture, osteoporotic fracture or hip fracture with only one 
fracture being counted per patient during follow-up (expressed as person-years).  A reduction in hip 
fracture risk that showed no interaction, with a flat reduction in risk across the range of baseline risk, 
would have suggested that factors other than treatment could have explained the observed effect. 
All analyses were conducted on an intention-to-treat basis with participants analysed according to 
the group to which they were randomised, irrespective of whether screening was completed.  The 
hazard function was assumed to be exp(β0 + β1·current time from baseline + β2·current age + β3·10-
year probability + β4·screening + β5·10-year probability·screening). The beta coefficients reflect the 
importance of the variables as in a logistic model, and βx = 0 denotes that the corresponding variable 
does not contribute to fracture risk. The variable “10-year probability·screening” tested for an 
interaction between screening effectiveness and baseline 10-year probability, handled as a 
continuous variable, by determining if β5<>0. Hazard ratios (HR) for screening effect and 95% 
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confidence intervals (95% CI) were computed as a continuous variable. For presentation, hazard 
ratios were shown at the 10th, 25th, 50th, 75th, and 90th percentile of fracture probability.  Further 
analyses explored the interaction between effectiveness and individual clinical risk factors within 
FRAX to determine the drivers of any potential interaction.  A similar analysis was conducted for any 
fracture and all incident osteoporotic fractures.  An exploratory analysis used the 10-year probability 
of major osteoporotic fracture instead of hip fracture as the baseline risk. 
 
Results 
Baseline Characteristics 
A total of 12,483 women were randomised, with 6,250 assigned to the control group and 6,233 to 
the screening arm.  The two groups were very similar at baseline (Table 2), with a mean age of 75 
years and mean BMI just under 27kg/m2 in both groups.  The completion rates for the risk factors in 
the questionnaire were all above 90%, ranging from 92.6% for parental history of hip fracture to 
99.9% for current smoking, and were similar in the screening and control arms.  The prevalence of 
FRAX risk factors in the control group ranged from 3.6% for average alcohol intake above 3 units per 
day to 23.4% for prior fracture, with very similar rates in the screening arm.  Following DXA 
measurement of femoral neck BMD in 2,817 women considered to be at moderate/high risk in the 
screening arm and recalculation of their FRAX hip fracture probabilities, 898 (14·4% of the screening 
arm) were identified to be at high risk and treatment recommended via their GP.  As expected, given 
the risk factors included in FRAX, these women tended to be older, have lower BMI and a higher 
prevalence of risk factors than those in the control arm (Table 2).   The mean FRAX 10-year 
probability of hip fracture, calculated without BMD, was more than two-fold higher in those 
identified at high risk compared to the control group. 
 
Baseline FRAX hip fracture probability and observed incidence of fractures 
Over 5 years of follow-up, 3.5%, 11.6% and 13.6% of the control arm sustained a new hip fracture, a 
new major osteoporotic fracture or any new osteoporotic fracture, respectively.  There was evidence 
of an increase in the observed incidence of hip and osteoporotic fractures in the control arm of the 
study (Figure 1) across the range of baseline FRAX hip fracture probability.  For example, the 
observed incidence of hip fracture was 6.5-fold higher in the highest quintile of baseline risk 
compared to the lowest quintile of risk.  The incidence of osteoporotic fractures also increased in a 
stepwise fashion across the quintiles of risk, but the increase was less marked than that seen in hip 
fractures, with only a 2.3-fold increase from lowest to highest quintile.  
 
Effectiveness and relationship to FRAX 
In Table 3, the effects of screening on various categories of fracture outcomes are shown, according 
to the baseline FRAX 10-year probability of a hip fracture.  The latter was entered as a continuous 
variable in the model, but for illustrative purposes the table shows the effect at various values of 
baseline probability.  Confidence estimates for the hazard ratio crossed unity at all probabilities for 
any fracture and osteoporotic fractures, with no evidence of an interaction between effectiveness 
and baseline FRAX hip fracture probability.   
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In contrast, the hazard ratio showed an interaction with baseline FRAX hip fracture probability for 
the outcome of hip fracture (p=0.021), and the upper confidence intervals were below unity at 
higher baseline risk (Table 3).  The interaction between screening effect and fracture probability for 
the outcome of hip fracture is shown in Figure 2.  At the median value of baseline hip fracture 
probability in the whole study population (6.3%), invitation for screening was associated with a 15% 
reduction in hip fracture risk albeit with a 95%CI that included the null.  At the 90th centile of the 
whole population risk (16.8%), there was a larger 33% reduction with a 95%CI that excluded the null, 
and at the 90th centile of baseline risk in the high-risk population (32%), the reduction was even 
higher at 53% (95%CI, 26-70%) (Figure 2). 
 
Components of screening effect 
In the context of evidence for an interaction between fracture probability and screening, we 
explored the potential drivers of the screening effect by examining the effect on hip fracture risk as a 
function of each variable within FRAX.  For the continuous variables of age and BMI, there was no 
evidence of an interaction with screening.  For example, at a BMI of 21kg/m2, screening reduced hip 
fracture risk by 24% (HR 0.76, 0.57-1.01), with a similar reduction at a BMI of 33kg/m2 (HR 0.73, 
0.47-1.14).  BMD could not be included in this analysis due to its absence in the vast majority of 
women in the control arm. 
The interaction between screening effectiveness on hip fracture risk and the dichotomous variables 
within FRAX are shown in Table 4.  For both prior fracture and parental history of hip fracture, there 
was evidence of an interaction, with greater effect on hip fracture reduction in those with the risk 
factor present.  In contrast, an interaction was observed for prevalent smoking whereby non-
smokers appeared to achieve the benefit while current smokers did not. 
 
 
Discussion 
 
The SCOOP study is the first prospective, randomised study to utilize the absolute risk of fracture, 
determined as the FRAX 10-year probability of hip fracture, as the means to target intervention to 
reduce fracture risk.  It has demonstrated the effectiveness of a community based, screening 
programme in women aged 70 to 85 years to reduce hip fractures, showing an average 28% 
reduction in incidence.(12)  Since intervention was targeted only at those women with high risk of 
hip fracture, we hypothesized that there would be an interaction between baseline risk and 
screening effectiveness, and the present analysis confirms this to be the case.  In individuals at very 
high risk of hip fracture, the estimated reduction in hip fracture risk was more than 50%.   
The study design of the SCOOP study has strengths and limitations.  The pragmatic design, in which 
a novel strategy was directly compared to existing practice, allowed assessment of the 
effectiveness of the screening pathway in reducing hip fracture risk.(12)  The main limitation is the 
lack of BMD measurements in some of the screening arm and the vast majority of the control arm, 
impairing the ability to undertake traditional post hoc subgroup analyses.  However, the use of 
FRAX probabilities as a continuous variable has been used to investigate interactions with 
treatment effects in a number of previous analyses,(4-11) and it is particularly apt for use in the 
current study where the exposure to treatment varied by the baseline risk.  The greater reduction 
in hip fracture risk at higher baseline risk, suggests that treatment rather than other factors 
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explained the observed effect.  
Exploratory examination of individual FRAX risk factors shows that the screening effectiveness was 
particularly influenced by the presence of the two most prevalent clinical risk factors in the high-
risk group, namely prior fracture and parental history of hip fracture.  For both risk factors, the 
effect of screening was greater in those with the risk factor present, raising questions about the 
potential underlying mechanism.   The most obvious and most likely mechanism, of course, is that 
these two factors drove the increased exposure to treatment in the intervention arm.  The well-
documented association between prior fracture and lower BMD might suggest that the greater 
effect was additionally mediated by the presence of a lower or osteoporotic BMD, but the 
evidence base for that is questionable for most anti-resorptive medications.(15)  The effective 
reduction in hip fracture risk in these 70-85 year old women with prior fracture is, however, 
supportive of the many international and national guidelines, including those in the UK, which 
state that all such women should be strongly considered for osteoporosis therapy, without 
necessarily measuring BMD, recently recognized as an unmet need in closing the osteoporosis 
treatment gap.(1,3,16,17)  There is certainly little evidence for a strong relationship between a 
parental history of hip fracture and BMD; indeed, meta-analysis shows that the effect of parental 
history on fracture risk is almost completely independent of BMD.(18)  A further potential 
explanation is that both factors may have influenced persistence as well as uptake of osteoporosis 
therapies, a hypothesis that will be explored in a subsequent analysis of the SCOOP study.  
Certainly the study participants represented motivated volunteers with a higher level of education, 
more fracture risk factors but less frequent smoking exposure than non-participants.(12)  
The results of the SCOOP study have potential impacts on future healthcare policy, including the 
implementation of a screening strategy for fracture prevention.  Indeed, a screening approach was 
recommended by NICE in 2012, when it proposed that all women aged 65 years or older and men 
aged 75 years or older should have a fracture risk assessment using the FRAX or QFracture tools.(19)  
In contrast to FRAX, the risk identified by the QFracture tool has not been examined for 
reversibility, intervention thresholds have not been defined, and QFracture does not permit the 
incorporation of BMD values into the risk assessment.   The SCOOP study readily demonstrates the 
reversibility of high risk identified by FRAX; interestingly, the intervention thresholds used in 
SCOOP, defined before the launch of the first NOGG guidance in 2008, ranged from a FRAX 10-year 
probability of hip fracture from 5.24% in 70-75 year-olds to 8.99% in 85 year-olds.  In the recently 
updated NOGG guidance, treatment is recommended in patients aged 70 years or older with a 10-
year major osteoporotic fracture probability of at least 20% or a hip fracture probability of at least 
5%,(3) thresholds that are associated with very acceptable cost-effectiveness as concluded by the 
recent NICE HTA on oral and intravenous bisphosphonates.(20)  
Preliminary health economic analyses of the SCOOP study indicate that the cost per prevented hip 
fracture is less than £8 000 and that the cost per QALY gained, estimated under a number of 
different scenarios, is less than £20 000.(12)  If one estimates that had screening been applied to the 
whole SCOOP study, then approximately 108 hip fractures would have been prevented.  The 
original target population for the study comprised 52 033 women aged 70-85 years, suggesting that 
if the SCOOP strategy was applied across the whole population of 70-85 year old women in the UK, 
estimated at 3.7 million (2016, mid-year estimate)(21), then almost 8000 hip fractures could be 
prevented each year; this could be further enhanced by mechanisms that extended the strategy to 
the two-thirds of eligible women who did not participate in the screening study, as well as 
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combining osteoporosis treatment with falls prevention in eligible individuals. 
In conclusion, the analysis demonstrates an interaction between baseline FRAX hip fracture 
probability and a subsequent reduction in hip fracture incidence in those at higher risk targeted for 
appropriate treatment.  Treatment success appears to have been driven by factors that might 
influence treatment adherence, a hypothesis that can be investigated in subsequent analyses.  
Future studies should examine how this FRAX-based approach can be made available to, or 
accessible by, the wider community to achieve greater reductions in the number of hip fractures in 
the UK and elsewhere. 
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Table 1.  Fracture and mortality outcomes in the SCOOP trial of screening in women aged 70-85 
years in England.(12) 
 
Outcomes Control 
(N=6250) 
Screening 
(N=6233) 
Hazard Ratio1 P-
value 
OP-related fractures 852 (13.6%) 805 (12.9%) 0.94 (0.85-1.03) 0.178 
Any clinical fracture 1002 (16.0) 951 (15.3) 0.94 (0.86-1.03) 0.18 
Hip fractures 218 (3.5%) 164 (2.6%) 0.72 (0.59-0.89) 0.002 
Deaths 525 (8.4%) 550 (8.8%) 1.05 (0.93-1.19) 0.436 
1Adjusted for Recruiting Region, Baseline FRAX Probability and Falls. 
OP – Osteoporosis (excludes fractures of the hands, feet, nose, skull or cervical vertebrae) 
 
 
 
 
 
Table 2.  Baseline characteristics of the control and screening arms, including details of those 
identified at high risk within the screening group. 
 
 Control 
(N=6250) 
Screening 
(N=6233) 
Screened High 
Risk (N= 898) 
Age (mean, SD) 75.5 (4.1) 75.4 (4.2) 77.2 (4.4) 
BMI (mean, SD) 26.7 (4.8) 26.7 (4.7) 24.4 (4.1) 
Self-reported prevalence (N, %) 
of: 
   
Fracture since age 50 1463 (23.4%) 1399 (22.4%) 409 (46.0%) 
Parental hip fracture 577  ( 9.2%) 585 ( 9.4%) 354 (41.6%) 
Smoking 290  ( 4.6%) 290 ( 4.7%) 86 ( 9.6%) 
Alcohol ≥3 units/day 225  ( 3.6%) 219 ( 3.5%) 60 ( 6.7%) 
Glucocorticoid Use 312  ( 5.0%) 316 ( 5.1%) 113 (13.3%) 
Rheumatoid Arthritis 410 ( 6.6%) 426 ( 6.8%) 79 ( 9.3%) 
Secondary Causes of OP 1408 (22.5%) 1483 (23.8%) 267 (29.7%) 
FRAX 10 year hip fracture 
probability (without BMD); 
mean(SD) 
 
 
8.5% (7.3%) 
 
 
8.5% (7.4%) 
 
 
17.9% (10.9%) 
    
OP – osteoporosis/osteoporotic. 
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Table 3. Hazard ratio (95%CI) between screening and control arms for any fracture, osteoporotic 
fracture and hip fracture at different values of FRAX 10-year probability (%) of a hip fracture 
calculated without BMD.  The p-value is for the interaction between screening and the outcome. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 4.  Hazard ratio between study arms (screening versus control) for hip fractures in those 
with and without the presence of a risk factor at baseline. 
 
 Hazard ratio (95% CI)  
FRAX Variable Absent Present P-value 
Previous fracture 0.87 (0.68, 1.12) 0.55 (0.38, 0.79) 0.040 
Parental hip fracture 0.79 (0.63, 0.99) 0.27 (0.13, 0.56) 0.0061 
Glucocorticoid use 0.76 (0.61, 0.94) 0.75 (0.28, 2.01) >0.30 
Smoking 0.72 (0.58, 0.88) 1.93 (0.78, 4.79) 0.037 
Alcohol 0.76 (0.62, 0.94) 0.68 (0.24, 1.92) >0.30 
Rheumatoid arthritis 0.72 (0.58, 0.90) 0.83 (0.40, 1.70) >0.30 
Secondary osteoporosis 0.77 (0.61, 0.97 0.71 (0.47, 1.08) >0.30 
 
 
Centile FRAX 
probability 
Any fracture Osteoporotic 
fracture 
Hip fracture 
10th 2.6 0.96 (0.86, 1.08) 0.97 (0.85, 1.09) 0.93 (0.71, 1.23) 
25th 3.8 0.96 (0.86, 1.07) 0.96 (0.86, 1.08) 0.91 (0.70, 1.17) 
50th 6.3 0.96 (0.87, 1.05) 0.96 (0.86, 1.06) 0.85 (0.68, 1.08) 
75th 10.5 0.95 (0.87, 1.04) 0.95 (0.86, 1.04) 0.77 (0.63, 0.95) 
90th 16.8 0.94 (0.84, 1.05) 0.93 (0.83, 1.05) 0.67 (0.53, 0.84) 
P-
value 
 >0.30 >0.30 0.021 
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Figure 1.  Observed incidence of osteoporotic and hip fractures during follow up in the control arm 
of the SCOOP study, within quintiles of baseline FRAX hip probability. 
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Figure 2.  Impact of screening on hip fracture compared to control arm, expressed as hazard ratio, 
across range of FRAX 10-year hip fracture probabilities at baseline, calculated without BMD.  There 
was evidence of an interaction of effectiveness with baseline probability (p=0.021).  The symbols 
indicate the range of baseline probabilities in the whole study population (closed symbols) and in 
the high-risk group identified by screening (open symbols).    
 
 
